App-Quantinova.ai

Falls characteristics of male and female patients with Parkinson’s disease (PD)

G. Alg - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Feasibility, tolerability and acceptance of a psychosocial intervention for people with Parkinsonian dementia: The INVEST trial.

S. McCormick - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

N/A

Fulfilment of Movement Disorder Society clinical diagnostic criteria for Parkinson’s disease in a large cohort study of recent onset cases.

N. Malek - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Functional lesional neurosurgery for tremor – a systematic review and meta-analysis

S. Schreglmann - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Genetic and Clinical Analysis of Cerebral Calcifications

V. Chelban - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Genotype-Phenotype correlations and expansion of the molecular spectrum of AP4M1-related Hereditary Spastic Paraplegia

S. Efthymiou - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Hereditary spastic paraplegia

N/A

Ghrelin and the IGF-1 axis in cognitive impairment in PD

F. Johnston - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

ghrelin

High-Pass Filtered Phase MR Imaging to Detect Longitudinal Motor Associations of Iron Accumulation in Parkinson’s Disease

A. Martin-Bastida - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Histological analysis of α-synuclein pathology in the circadian system in Parkinson’s disease

E. De Pablo-Fernandez - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Holmes’ tremor and olivary hypertrophy: lessons from this neuroanatomical correlation

R. Ellis - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Hypertension and Parkinson’s disease

B. Giordano - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

IGF-1 levels are associated with CSF pathology and executive dysfunction in de novo Parkinson’s disease patients

G. Dervenoulas - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Executive dysfunction

Mecasermin

Impulse Control Disorders in Early Onset and Familial PD

R. Rees - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

In vivo evaluation of tau and amyloid pathology in Corticobasal Syndrome

F. Niccolini - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Corticobasal Syndrome

AV-1451

Incorporating Specialist Independent Prescribing Pharmacist (SIPP) sessions into the Movement Disorder Service

D. Fletcher - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Increased BMI May Protect Against Parkinson’s Disease: Evidence From A Mendelian Randomisation Study

A. Noyce - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Intention Awareness in Parkinson’s Disease

S. Di Costa - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Is there a significant relationship between weight loss and prevalence of side effects of Parkinsonian medication? A retrospective, single-centre analysis, South Wales, UK.

B. Schroeder - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Movement disorders

N/A

Levodopa responsiveness in Parkinson’s disease is significantly impaired in those with diabetes and increased vascular risk.

N. Malek - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Parkinson's disease

Levodopa

Longitudinal comparison of 11C-PE2I and 18F-DOPA PET for assessing severity and rate of disease progression in patients with Parkinson’s disease

W. Li - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Filters

45280 Abstracts